MEI Pharma Announces $15.2 Million Registered Offering of Common Stock San Diego – April 5, 2013 – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today an underwritten registered...
NxStage Completes Move to Direct Sales In UK Company to Leverage Recent CE Mark Approvals for System One Innovations LAWRENCE, Mass., April 8, 2013 /PRNewswire/ — NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products,...
iRhythm Secures $16 Million in Funding Led by Norwest Venture Partners to Fuel Continued Market and Technology Expansion Adoption of Zio Patch System Reaches New Milestone – Greater Than 20 Million Patient Hours of Monitoring SAN FRANCISCO – April 10, 2013 –...
MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC San Diego – April 10, 2013 – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology...
Oxford Immunotec wins 2013 Red Herring Top 100 Award Oxford, UK and Marlborough, MA – 11 April 2013 – Oxford Immunotec is pleased to announce today that it has won a place in Red Herring‘s Top 100 Europe list for 2013. Red Herring’s Top 100 Europe list has...
Recent Comments